**Abstract**

Schizophrenia is a devastating mental disorder with high heritability estimate up to 80%. Secretory pathway of peptide hormones and neuropeptides in brain is regulated by chromogranin proteins. *Chromogranin B* (*CHGB*), a member of chromogranin family gene, is proposed as one of the candidate genes for the risk of schizophrenia. In a genome wide association study performed in a Japanese population, genetic variant (microsatellite: D20S95) near *CHGB* could be a potential genetic marker for the schizophrenia development.

In the current study, 15 SNPs of *CHGB* were genotyped in 310 schizophrenia patients and 604 healthy controls to investigate the association with the schizophrenia susceptibility. Statistical analysis has revealed that four genetic variants (*rs446659*, *rs6133278* (D145N), *rs910122* (R178Q), *rs2821*) were associated with the reduced risk of schizophrenia (OR=0.72--0.78, *p*=0.002--0.02). In the subgroup analysis, five genetic variants (*rs236141*, *rs446659*, *rs6085323*, *rs910122* (D178Q), *rs2821*) and a haplotype (*ht3*) showed more protective effect on the schizophrenia in male subjects (OR=0.52--0.74, *p*=0.002--0.05), but not in female subjects.

Our results demonstrated that genetic variants in *CHGB* showed gender-specific effect to the reduced risk of schizophrenia, which could be a useful preliminary result for further study.

**Keywords:** Single nucleotide polymorphisms (SNPs), *Chromogranin B* (*CHGB*), schizophrenia, gender-specific marker, male
